This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Beat in the Cards for Perrigo (PRGO) in Q1 Earnings?
by Zacks Equity Research
Perrigo's (PRGO) product purchases and introductions in the Rx segment might shoot up sales in the near future.
Jazz Pharmaceuticals (JAZZ) Q1 Earnings: What's in Store?
by Zacks Equity Research
Investor focus is likely to be on Xyrem's performance, the lead product of Jazz Pharmaceuticals (JAZZ) for excessive daytime sleepiness. Also, the company's pipeline progress might grab attention.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Catalyst (CPRX) is expected to report first-quarter 2018 results on May 9, after the market closesa and investor's focus will be on pipeline and regulatory updates during the earnings call.
Madrigal (MDGL) Q1 Earnings: Disappointment in the Cards?
by Zacks Equity Research
In want of an approved product in Madrigal's (MDGL) portfolio, investors' entire focus on first-quarter earnings call to revolve around the company's lead pipeline candidate, MGL-3196.
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
Although Arena's (ARNA) only approved product, Belviq, puts up a dismal show so far, the company's efforts to improve the drug's performance might drive the stock in Q1.
Will ACADIA (ACAD) Disappoint Investors This Earnings Season?
by Zacks Equity Research
ACADIA (ACAD) is expected to release first-quarter 2018 results on May 8 and provide updates on its drug, Nuplazid.
Is a Beat in Store for Adverum (ADVM) This Earnings Season?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) is expected to report first-quarter 2018 results, on May 8 and provide updates on its pipeline candidates.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.
GW Pharma (GWPH) Q2 Earnings: Is a Turnaround in the Cards?
by Zacks Equity Research
GW Pharma (GWPH) is expected to report its fiscal second-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.
What's in Store for Intercept (ICPT) This Earnings Season?
by Zacks Equity Research
Investors are expected to focus on Ocaliva sales when Intercept (ICPT) reports first-quarter results (expected on May 3).
Zoetis (ZTS) Gears Up for Q1 Earnings: What's in Store?
by Zacks Equity Research
Zoetis' (ZTS) top line in the first quarter is likely to be driven by continued demand for dermatology portfolio and product launches.
AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) first drug, Fotivda for the first-line treatment of RCC is likely to have a favorable impact on first-quarter results.
Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why
by Zacks Equity Research
Let us look at the factors that have led to the increase in share price of Emergent (EBS).
Why Is Emergent Biosolutions (EBS) Up 8% Since Its Last Earnings Report?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inovio's Influenza Vaccine Shows Potential, Shares Rally
by Zacks Equity Research
Inovio Pharmaceuticals' (INO) universal influenza vaccine leads to broad protective antibody responses against all major deadly strains of H1 virus.
Exact Sciences (EXAS) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
The shares of Exact Sciences (EXAS) rose over 5% yesterday.
Illumina (ILMN) Looks Good: Stock Adds 6.9% in Session
by Zacks Equity Research
Illumina (ILMN) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.
Emergent Starts Phase II Study on Anti-influenza Candidate
by Zacks Equity Research
Emergent (EBS) initiates a phase II dose-ranging trial to evaluate the safety, pharmacokinetics and clinical benefit of its investigational FLU-IGIV to treat influenza virus infection.
5 Reasons to Pick Emergent as an Investment-Worthy Stock
by Zacks Equity Research
Other than a bullish rank, there are several factors that make Emergent (EBS) a solid investment in 2018.
New Strong Buy Stocks for January 2nd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
2 Biotech Stocks with Month-Long Upward Estimate Revisions
by Zacks Equity Research
Although the biotech sector initially picked up this year, it witnesses a correction since October. However, it is a good idea to select stocks witnessing positive estimate revisions for a month now.
Should You Get Rid of Peregrine Pharmaceuticals (PPHM) Now?
by Zacks Equity Research
Peregrine Pharmaceuticals (PPHM) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and year.
Five Marvelous Momentum Stocks to Buy Now
by David Bartosiak
These five Zacks Rank #1 (Strong Buy) stocks are surging on huge demand and breaking higher
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 7.5%
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.